Evidence map›Paper›PMID 28658471›Full record

ArticleJAMA psychiatry2017

Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder.

Yi Lu, Arvid Sjölander, Martin Cederlöf, Brian M D'Onofrio, Catarina Almqvist, Henrik Larsson, Paul Lichtenstein

Abstract read
In one paragraph

Article in JAMA psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study.The British journal of psychiatry : the journal of mental science · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Attention-deficit/hyperactivity disorder.Nature reviews. Disease primers · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yi LuDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden2Statistical Genetics, Genetics, and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Arvid SjölanderDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Martin CederlöfDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Brian M D'OnofrioDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden3Department of Psychological and Brain Sciences, Indiana University, Bloomington.
Catarina AlmqvistDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden4Pediatric Allergy and Pulmonology Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Henrik LarssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden5School of Medical Sciences, Örebro University, Örebro, Sweden.
Paul LichtensteinDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Funding

Risks and Benefits of ADHD Medication for Psychiatric and Neurologic ProblemsR01MH102221 · NIMH · TRUSTEES OF INDIANA UNIVERSITY · PI D'ONOFRIO, BRIAN M, LARSSON, HENRIK · 2014 to 2017
$1.7M
NIMH NIH HHS R01 MH102221
6 · The paper itself

Abstract

Importance: Individuals with attention-deficit/hyperactivity disorder (ADHD) are at greater risk for academic problems. Pharmacologic treatment is effective in reducing the core symptoms of ADHD, but it is unclear whether it helps to improve academic outcomes. Objective: To investigate the association between the use of ADHD medication and performance on higher education entrance tests in individuals with ADHD. Design, Setting, and Participants: This cohort study observed 61 640 individuals with a diagnosis of ADHD from January 1, 2006, to December 31, 2013. Records of their pharmacologic treatment were extracted from Swedish national registers along with data from the Swedish Scholastic Aptitude Test. Using a within-patient design, test scores when patients were taking medication for ADHD were compared with scores when they were not taking such medication. Data analysis was performed from November 24, 2015, to November 4, 2016. Exposures: Periods with and without ADHD medication use. Main Outcomes and Measures: Scores from the higher education entrance examination (score range, 1-200 points). Results: Among 930 individuals (493 males and 437 females; mean [SD] age, 22.2 [3.2] years) who had taken multiple entrance tests (n = 2524) and used ADHD medications intermittently, the test scores were a mean of 4.80 points higher (95% CI, 2.26-7.34; P < .001) during periods they were taking medication vs nonmedicated periods, after adjusting for age and practice effects. Similar associations between ADHD medication use and test scores were detected in sensitivity analyses. Conclusions and Relevance: Individuals with ADHD had higher scores on the higher education entrance tests during periods they were taking ADHD medication vs nonmedicated periods. These findings suggest that ADHD medications may help ameliorate educationally relevant outcomes in individuals with ADHD.

Indexed as

RegistriesAdultAptitude TestsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityCase-Control StudiesCentral Nervous System StimulantsFemaleHumansMalePsychomotor PerformanceYoung AdultAtomoxetine HydrochlorideCentral Nervous System Stimulants

Identifiers

PMID28658471
PMCPMC5710548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.